

# Compartmentalization of Phosphatidylinositol 4,5-Bisphosphate Signaling Evidenced Using Targeted Phosphatases\*

Received for publication, July 31, 2008. Published, JBC Papers in Press, August 21, 2008, DOI 10.1074/jbc.M805921200

Corey M. Johnson<sup>‡</sup>, Gurunadh R. Chichili<sup>‡</sup>, and William Rodgers<sup>‡§¶1</sup>

From the <sup>‡</sup>Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, and the Departments of <sup>§</sup>Pathology and <sup>¶</sup>Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104

Phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) is a prevalent phosphoinositide in cell membranes, with important functions in cell signaling and activation. A large fraction of PIP<sub>2</sub> associates with the detergent-resistant membrane “raft” fraction, but the functional significance of this association remains controversial. To measure the properties of raft and nonraft PIP<sub>2</sub> in cell signaling, we targeted the PIP<sub>2</sub>-specific phosphatase Inp54p to either the raft or nonraft membrane fraction using minimal membrane anchors. Interestingly, we observed that targeting Inp54p to the nonraft fraction resulted in an enrichment of raft-associated PIP<sub>2</sub> and striking changes in cell morphology, including a wortmannin-sensitive increase in cell filopodia and cell spreading. In contrast, raft-targeted Inp54p depleted the raft pool of PIP<sub>2</sub> and produced smooth T cells void of membrane ruffling and filopodia. Furthermore, raft-targeted Inp54p inhibited capping in T cells stimulated by cross-linking the T cell receptor, but without affecting the T cell receptor-dependent Ca<sup>2+</sup> flux. Altogether, these results provide evidence of compartmentalization of PIP<sub>2</sub>-dependent signaling in cell membranes such as predicted by the membrane raft model.

The lipid phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>)<sup>2</sup> is important for cell growth and viability (1), exemplified by its role as the precursor for the second messengers inositol 1,4,5-triphosphate, diacylglycerol, and phosphatidylinositol 3,4,5-bisphosphate (PIP<sub>3</sub>) (2, 3). PIP<sub>2</sub> is also a cofactor for activation of select membrane proteins (4); this includes proteins that function in tethering actin filaments to the plasma membrane, such as the ERM (ezrin-radixin-moesin) proteins (5) and the filamins (6). Other PIP<sub>2</sub>-regulated membrane proteins include

WASP and WAVE, which serve as effectors for the Rho GTPases in actin polymerization (7). Altogether, the properties of PIP<sub>2</sub> in regulating actin-associated membrane proteins underlie its important role in establishing interactions between the plasma membrane and actin cytoskeleton (8).

The diverse and important functions of PIP<sub>2</sub> underscore the importance of maintaining proper regulation of this lipid. As cell membranes are structurally heterogeneous (9), spatially concentrating PIP<sub>2</sub> in discrete domains could be one mechanism for regulating PIP<sub>2</sub> functions. Notably, a significant pool of the PIP<sub>2</sub> associates with the detergent-resistant membrane (DRM) fraction postulated to represent cholesterol-dependent membrane domains, or membrane “rafts” (10–12). As membrane rafts serve as “reaction vessels” in the plasma membrane (13), enrichment of PIP<sub>2</sub> in rafts may augment PIP<sub>2</sub>-dependent pathways and production of second messengers. Alternatively, rafts may function in regulating PIP<sub>2</sub> signaling by sequestering it from activators in steady-state conditions, such as evidenced with certain membrane-associated kinases (14, 15).

Membrane domains such as rafts are often below the resolution of light microscopy, making direct observation of these structures difficult. Accordingly, many of the properties of the rafts have been deciphered from measurements of DRMs. One shortcoming with this approach is that the detergents used to prepare the DRMs also perturb the physical properties of the bilayer. Accordingly, it has been suggested the detergent-insoluble membranes are an artifact of sample preparation and not representative of domains in intact membranes (16, 17). Similarly, studies of rafts often utilize cholesterol-depleting agents such as methyl- $\beta$ -cyclodextrin, and these compounds can cause nonspecific changes in membrane structure and function (16–19). In one example, it was shown that treating cells with methyl- $\beta$ -cyclodextrin alters the membrane distribution of PIP<sub>2</sub> and its availability to PIP<sub>2</sub>-binding proteins (19). However, it is not known whether this property represents a cholesterol-dependent property of PIP<sub>2</sub> functions or a nonspecific effect from the drug treatment.

Notably, other data show that DRMs are in fact representative of discrete membrane domains (20). For example, imaging studies measuring the plasma membrane distribution of labeled proteins and lipids show a specific clustering of DRM-associated molecules. In one recent study, using fluorescence resonance energy transfer, we showed a specific cholesterol-dependent co-clustering of reporter molecules in the plasma membrane by membrane-anchoring signals that target fluores-

\* This work was supported, in whole or in part, by National Institutes of Health Grant RO1 GM070001. This work was also supported by American Heart Association Grant 0625648Z. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Sec. 1734 solely to indicate this fact.

<sup>1</sup> To whom correspondence should be addressed: Oklahoma Medical Research Foundation, 825 NE 13th St., MS 45, Oklahoma City, OK 73104. Tel.: 405-271-3550; Fax: 405-271-7417; E-mail: william-rodgers@omrf.org.

<sup>2</sup> The abbreviations used are: PIP<sub>2</sub>, phosphatidylinositol 4,5-bisphosphate; PIP<sub>3</sub>, phosphatidylinositol 3,4,5-trisphosphate; DiI-C<sub>16</sub>, 1,1'-dihexadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; DRM, detergent-resistant membrane; GFP, green fluorescent protein; PI3K, phosphatidylinositol 3-kinase; TCR, T cell receptor; PLC, phospholipase C; PH, pleckstrin homology.

cent proteins to DRMs (21). One example was the N-terminal membrane-anchoring signal of the Src family kinase Lck. However, an alternative membrane-anchoring signal from Src, which does not target molecules to DRMs, also did not cause a cholesterol-dependent clustering of fluorescent proteins. In total, results from imaging studies show that membrane rafts are heterogeneous in nature, ranging in size from nanoclusters that are on the order of a few nanometers in size to nanodomains that have a diameter of ~50 nm and to micron-size macrodomains (22, 23). Imaging experiments have also shown colocalization of PIP<sub>2</sub> with raft markers in both the plasma membrane and intracellular trafficking vesicles (24–27), thus consistent with the notion that PIP<sub>2</sub> is enriched in rafts.

Although both membrane fractionation experiments and imaging studies show that PIP<sub>2</sub> is enriched in rafts, the biological significance of its raft association is poorly understood. A useful approach to measuring PIP<sub>2</sub> functions in cells while avoiding chemical treatments is to alter membrane PIP<sub>2</sub> levels using membrane-targeted PIP<sub>2</sub>-specific phosphatases (1). One example has been targeting the catalytic domain of the yeast PIP<sub>2</sub>-specific phosphatase Inp54p to the plasma membrane using the membrane-anchoring signal of the Src family kinase Lyn (Lyn-Inp54p) (8, 28). Expression of membrane-anchored Inp54p has demonstrated a role for PIP<sub>2</sub> in maintaining interactions between the plasma membrane and underlying actin cytoskeleton (8). Interestingly, the membrane-anchoring signal of Lyn, which consists of myristoylation of an N-terminal glycine and palmitoylation of an adjacent cysteine, is also an effective raft-targeting sequence (29, 30). Accordingly, the discrete phenotypes evidenced by expression of Lyn-Inp54p may reflect changes specific to the raft-associated pool of PIP<sub>2</sub>.

Using membrane-targeting sequences from separate Src family kinases to target Inp54p to cell membranes, we observed that raft- and nonraft-targeted Inp54p caused distinct changes in the membrane pools of PIP<sub>2</sub> and cell phenotype. For example, enrichment of the raft pool of PIP<sub>2</sub> by nonraft Inp54p increased membrane ruffling and cell spreading, and depletion of this pool by raft-targeted Inp54p inhibited the ruffling as well as capping in stimulated T cells. Altogether, our findings provide evidence of sequestering of PIP<sub>2</sub>-dependent functions between separate membrane fractions in a manner consistent with the membrane raft model but while avoiding artifacts associated with detergent treatments of cell membranes.

## MATERIALS AND METHODS

**Gene Construction and Expression**—The Inp54p constructs each contained a minimal membrane-anchoring signal, followed by green fluorescent protein (GFP) and finally the soluble domain of Inp54p (residues 1–331) that included its active site (see Fig. 1A). The membrane anchors were either the first 10 amino acids of Lck (L<sub>10</sub>) or the first 15 amino acids of c-Src (S<sub>15</sub>) (31). The following oligonucleotides were used for amplifying the DNA sequence encoding Inp54p: 5'-ACATCAGAATTC-AACAACAACAACAACGAATTGGAAGGT (sense) and 5'-TCTAGTCTCGAGTTACGGCACTGGCGTCCCTGTAG (antisense). The L<sub>10</sub>-GFP and S<sub>15</sub>-GFP coding sequences were amplified from previously described genes (31) using the following primers: 5'-ACATCAGCATCCAGAATG-

GGGAGCAAGAGCAA (S<sub>15</sub>, sense), 5'-ACATCACCCGCGG-AGAATGGGCTGTGTCTGCAGC (L<sub>10</sub>, sense), and 5'-GCTAGTAAAGCTTCTTGTAACAGCTCGTCCAT (GFP, antisense). The underlined nucleotides identify the restriction sites for EcoRI, XhoI, BamHI, SacII, and HindIII, respectively, which were used for directional cloning in pLenti (Invitrogen). The genes were subcloned into pLenti and oriented for control of expression by a 5'-long terminal repeat.

**Cell Cultures and Transfections**—Jurkat T cells (clone E6-1) were cultured in RPMI 1640 medium with 10% fetal bovine serum and supplemented with L-glutamine and antibiotics. 293T cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and supplemented with antibiotics. All cells were maintained at 37 °C in the presence of 5% CO<sub>2</sub>.

For gene expression, 293T cells were transfected by CaPO<sub>4</sub> (Invitrogen) using 10 μg of plasmid DNA for a 50% confluent 6-cm plate. Jurkat cells were transfected by electroporation as described (32). Following transfection, Jurkat cells were cultured in AIM V medium (Invitrogen) for 48 h and then harvested for experimentation.


**Membrane Fractionation**—Approximately 10<sup>7</sup> cells were lysed by incubation at 4 °C for 20–30 min with 750 μl of 1% Triton X-100. Next, the samples were homogenized in a Dounce homogenizer (eight strokes) and centrifuged for 5 min at 4000 rpm (Eppendorf Model 5417C, Brinkmann Instruments). The supernatant was collected, and the raft and nonraft membrane fractions were separated by equilibrium centrifugation using a discontinuous sucrose gradient (14). Following centrifugation, the gradients were fractionated from the top.

**PIP<sub>2</sub> Measurement**—Phosphoinositide extraction was performed as described (33) with minor adjustments. In brief, 3 ml of ice-cold chloroform/methanol/HCl (2:4:0.1) was added to the pooled gradient fractions corresponding to the raft (gradient fractions 2–4) (see Fig. 1 in Ref. 21) and nonraft (gradient fractions 7–10) (see Fig. 1 in Ref. 21) membrane fractions. The samples were mixed vigorously for 30 s and then incubated on ice for 15 min. To induce a phase separation, 1 ml of ice-cold chloroform was added with 1 ml of 1.76% KCl, 100 mM citric acid, 100 mM Na<sub>2</sub>HPO<sub>4</sub>, 5 mM EDTA, and 5 mM tetrabutylammonium hydrogen sulfate. Samples were mixed for 30 s and incubated on ice for 5 min. Samples were then centrifuged for 10 min at 2000 × g.

After centrifugation, the organic phase (bottom) was collected, dried, and resuspended in a minimal volume (~10 μl) of solvent (4:3:1 chloroform/methanol/water). Samples were spotted onto nitrocellulose membrane using a Bio-Rad dot blot vacuum manifold. PIP<sub>2</sub> was detected by immunoblotting using a monoclonal antibody (Echelon Biosciences Inc., Salt Lake City, UT) at a final concentration of 1 μg/ml, followed by a biotinylated secondary antibody. The final step was horseradish peroxidase conjugated to streptavidin (Vector Laboratories, Burlingame, CA). The membrane was developed using enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK) and detected with a Lumi-Imager F1 workstation (Roche Applied Science, Mannheim, Germany).

**Cell Labeling and Imaging**—Imaging was performed using either a Zeiss LSM510 microscope or a Zeiss Axioplan 2i

## Membrane Rafts in PIP<sub>2</sub> Signaling



**FIGURE 1. Membrane-targeted Inp54p molecules cause distinct changes in raft and nonraft PIP<sub>2</sub>.** *A*, targeting of the PIP<sub>2</sub>-specific phosphatase Inp54p to raft and nonraft membrane fractions. The constructs contained either the first 10 amino acids of Lck (L<sub>10</sub>) or the first 15 amino acids of c-Src (S<sub>15</sub>) for membrane association, followed by GFP and finally the soluble domain of Inp54p (L<sub>10</sub>-Inp54p and S<sub>15</sub>-Inp54p, respectively). L<sub>10</sub> targets proteins to the detergent-resistant raft fraction, and S<sub>15</sub> restricts proteins to the detergent-soluble nonraft fraction (21). Myr and Palm indicate sites of myristoylation and palmitoylation, respectively, of the indicated residues in the membrane-anchoring signals. A third construct consisting of membrane-anchored GFP (L<sub>10</sub>-GFP) was used as a control. *B*, measurement of changes in membrane PIP<sub>2</sub> pools by L<sub>10</sub>-Inp54p and S<sub>15</sub>-Inp54p (upper panel). 293T cells expressing either L<sub>10</sub>-Inp54p or S<sub>15</sub>-Inp54p were lysed with Triton X-100, and the raft and nonraft membrane fractions were separated by sucrose gradient equilibrium centrifugation. Following separation, the gradient fractions containing the respective membrane fractions were pooled and extracted, and PIP<sub>2</sub> was measured in each by immunoblotting. PIP<sub>3</sub>, PIP<sub>2</sub>, and phosphatidylinositol 4-phosphate (PI4P) represent purified lipids that were measured in parallel as controls for antibody specificity. Immunoblotting a range of the PIP<sub>2</sub> standards together with a set of samples from cells that expressed S<sub>15</sub>-Inp54p showed that PIP<sub>2</sub> extracted from cells was within the dynamic range of the measure (lower panel). In the accompanying plot, values for the S<sub>15</sub>-Inp54p raft and nonraft fractions are represented by open circles. A.U. denotes arbitrary units. *C*, quantitation of the immunoblot in *B*. *D*, measurement of membrane PIP<sub>2</sub> pools for cells expressing L<sub>10</sub>-GFP and S<sub>15</sub>-GFP as a control for any sequestering of PIP<sub>2</sub> by the S<sub>15</sub> sequence. Quantitation of the dots is shown in the graph below. *E*, average of measurements from three separate trials. These results are represented as the fraction of total PIP<sub>2</sub> that was raft-associated. *F*, total lipids measured for PIP<sub>2</sub>. In *E* and *F*, the error bars represent S.E. \*,  $p \leq 0.05$  by Student's *t* test; NS (not significant),  $p > 0.38$ .

upright fluorescence microscope (Oklahoma Medical Research Foundation Cell Imaging Core Facility). The images were collected using a 100 $\times$  oil objective (1.4 numerical aper-

ture). Three-dimensional projection images were generated from confocal stacks that were collected by optically sectioning along the *z* axis at an interval of 0.24  $\mu$ m. Before three-dimensional reconstruction, the confocal stacks were deconvolved using AutoDeblur (AutoQuant Imaging, Inc., Watervliet, NY). The projection images were produced using iVision (BioVision Technologies, Exton, PA). All other image processing and quantitation were performed using iVision.

For imaging of T cell capping, cells were stimulated using OKT3-coated polystyrene beads as described (34). Following stimulation, the samples were fixed using 2% paraformaldehyde and then permeabilized with 0.2% Triton X-100 in phosphate-buffered saline. F-actin was labeled by incubation with 0.1  $\mu$ g/ml Texas Red-labeled phalloidin (Invitrogen) for 30–45 min at 37  $^{\circ}$ C. Capping was quantitated by dividing the average fluorescence intensity of the plasma membrane in contact with the OKT3-coated bead by the average fluorescence intensity of the remaining plasma membrane. Cells were scored positive for capping if the ratio was 1.5 or greater. Histograms of relative fluorescence enrichment in the caps were prepared using IGOR Pro software (WaveMetrics, Inc., Lake Oswego, OR).

**Ca<sup>2+</sup> Flux Measurements**—For detection of Ca<sup>2+</sup> during stimulation, Jurkat T cells were labeled by incubation for 30 min in 2  $\mu$ M Indo-1 (Invitrogen) at 37  $^{\circ}$ C. Following labeling, the cells were suspended in 15 mM HEPES (pH 7.4) supplemented with 140 mM NaCl, 5 mM KCl, 1 mM MgCl<sub>2</sub>, 1.8 mM CaCl<sub>2</sub>, and 10 mM glucose. The Ca<sup>2+</sup> flux was measured by flow cytometry (MOFLO, DakoCytomation, Fort Collins, CO) based on the change in the fluorescence emission at 475 and 400 nm. Excitation for Indo-1 was at 390 nm. To limit the measurements to transfected cells, the samples were gated

on those expressing GFP. GFP was detected using 488 nm excitation with a green band-pass filter centered at 530 nm for emission. The temperature of the instrument was maintained




at 37 °C, and the flow rate was maintained by a base sheath pressure of 60 ± 1 p.s.i. A base line was achieved by passing the cells for ~1 min prior to addition of OKT3. After the OKT3-dependent flux was complete, ionomycin was added to determine the maximal flux capacity of the cells. Store-operated channel Ca<sup>2+</sup> flux was measured in the same manner as the total flux, except the buffer contained 0.05 μM EGTA rather than CaCl<sub>2</sub>. Following the initial flux from release of intracellular stores, Ca<sup>2+</sup> (1 mM stock) was added back to the sample to a final concentration of 10 mM.

## RESULTS

**Membrane Raft- and Nonraft-targeted Inp54p Molecules Cause Distinct Changes in PIP<sub>2</sub> Membrane Pools**—The membrane-targeted Inp54p molecules used in this study are illustrated in Fig. 1A. Specifically, we targeted Inp54p to cell membranes using either the N-terminal 10 residues of Lck (L<sub>10</sub>) or the N-terminal 15 residues of Src (S<sub>15</sub>). We have described the L<sub>10</sub> and S<sub>15</sub> membrane-anchoring signals previously (31) and showed that the L<sub>10</sub> sequence efficiently targets peptides to the DRM raft fraction and that the S<sub>15</sub> sequence limits peptides to the detergent-soluble nonraft fraction. As a control to identify changes in the PIP<sub>2</sub> pools and cell phenotype that were specific to the phosphatase activity, we expressed a third construct containing the L<sub>10</sub> anchor and GFP but no Inp54p (L<sub>10</sub>-GFP).

To determine the effect of the targeted Inp54p molecules on the raft and nonraft pools of PIP<sub>2</sub>, we measured the PIP<sub>2</sub> present in each membrane fraction after expressing L<sub>10</sub>-Inp54p, S<sub>15</sub>-Inp54p, or L<sub>10</sub>-GFP. For this experiment, we extracted the lipids of the raft and nonraft fractions following separation of the membrane fractions by sucrose gradient equilibrium centrifugation (see “Materials and Methods”). In Fig. 1B is an immunoblot measuring the PIP<sub>2</sub> present in each membrane fraction of transfected cells, and in Fig. 1C are the results from quantitating the blot. These data show that expression of L<sub>10</sub>-Inp54p decreased the raft-associated pool of PIP<sub>2</sub>, whereas S<sub>15</sub>-Inp54p both increased the amount of raft PIP<sub>2</sub> and decreased the PIP<sub>2</sub> in the nonraft fraction. Furthermore, the changes in raft and nonraft PIP<sub>2</sub> by S<sub>15</sub>-Inp54p were specific to the Inp54p domain because expression of a GFP molecule containing the S<sub>15</sub> anchor alone (S<sub>15</sub>-GFP) demonstrated similar levels of PIP<sub>2</sub> in each fraction as L<sub>10</sub>-GFP (Fig. 1, D and E). By averaging the results from several trials, we determined that L<sub>10</sub>-Inp54p decreased by 10% the fraction of total PIP<sub>2</sub> that was raft-associated, whereas S<sub>15</sub>-Inp54p increased this ratio by 2-fold (Fig. 1E). Notably, neither Inp54p construct caused a statistically significant change in the total PIP<sub>2</sub> levels of the cells (Fig. 1F).


**T Cells Demonstrate Distinct Morphologies and Cell Spreading Based on Targeted Inp54p Expression**—In T cells, PIP<sub>2</sub> and its effectors are necessary for cell activation (35–37). To determine whether raft and nonraft pools of PIP<sub>2</sub> in T cells are functionally distinct, we measured Jurkat T cells expressing L<sub>10</sub>-Inp54p, S<sub>15</sub>-Inp54p, or control L<sub>10</sub>-GFP. Interestingly, we observed distinct morphologies from expression of the separate Inp54p molecules (Fig. 2A). For example, T cells that expressed raft-targeted L<sub>10</sub>-Inp54p (Fig. 2A, left panel) often exhibited a smooth morphology that was void of the membrane ruffles and filopodia that occurred in control cells that expressed L<sub>10</sub>-GFP



**FIGURE 2. Cell morphologies from expression of the membrane-targeted Inp54p molecules.** A, projection images of Jurkat T cells that expressed L<sub>10</sub>-Inp54p, S<sub>15</sub>-Inp54p, or L<sub>10</sub>-GFP. The images were acquired using confocal microscopy and detected using GFP fluorescence. The white and yellow arrowheads indicate filopodia and membrane ruffling, respectively. B, quantitation of filopodia in transfected T cells. Filopodia in cells that expressed L<sub>10</sub>-Inp54p, S<sub>15</sub>-Inp54p, L<sub>10</sub>-GFP, or S<sub>15</sub>-GFP were counted using wide-field microscopy. The graph represents the average of 90 cells measured in three independent trials. The error bars represent S.E. \*\*\*,  $p \leq 0.005$  by Student's *t* test; N.S., not significant. C, representative example of the membrane blebs observed in cells that expressed L<sub>10</sub>-Inp54p. The right panel is a higher magnification of the region indicated by the square in the left panel. D, confocal images of a T cell double-labeled with S<sub>15</sub>-Inp54p and cholera toxin conjugated to Texas Red (CTX-TR). The arrowheads indicate examples of double-labeled filopodia. E, confocal images of Jurkat cells double-labeled with S<sub>15</sub>-Inp54p and DiIC<sub>16</sub>. The arrowheads indicate filopodia labeled with DiIC<sub>16</sub> but not S<sub>15</sub>-Inp54p. Scale bars = 5 μm.

(right panel). We also observed membrane blebs in the L<sub>10</sub>-Inp54p samples (Fig. 2C), similar to those described for cells expressing Lyn-Inp54p (8). The blebs represent regions of the plasma membrane that bubble outward and can be due to poor association of the membrane with the underlying actin cytoskeleton (38).


In contrast to L<sub>10</sub>-Inp54p, T cells that expressed S<sub>15</sub>-Inp54p exhibited a striking morphology that contained numerous filopodia and extensive membrane folding compared with that of the control samples (Fig. 2A, middle panel). We quantitated the effects of each Inp54p construct on cell morphology by counting the number of filopodia in T cells expressing either L<sub>10</sub>-Inp54p or S<sub>15</sub>-Inp54p. As controls, we expressed either L<sub>10</sub>-GFP or S<sub>15</sub>-GFP. These measurements showed an increase in filopodial number upon S<sub>15</sub>-Inp54p expression, whereas L<sub>10</sub>-Inp54p caused a decrease in filopodial number relative to the control samples (Fig. 2B).



**FIGURE 3. S<sub>15</sub>-Inp54p-dependent filopodial growth is PI3K-dependent.** A, representative images of T cells expressing S<sub>15</sub>-Inp54p that were treated with wortmannin (*Wm*) or treated with wortmannin, washed, and allowed to recover in growth media for 2 h (*Recovery*). Scale bar = 5 μm. B, quantitation of the number of filopodia in each set of conditions. The data represent the average of 90 cells measured in three separate trials. \*\*\*, *p* ≤ 0.005 by Student's *t* test.

The increase in cell filopodia upon S<sub>15</sub>-Inp54p expression coincided with an increase in raft-associated PIP<sub>2</sub> (Fig. 1), suggesting that the filopodia may contain raft-enriched membrane. To test this hypothesis, we stained T cells expressing S<sub>15</sub>-Inp54p with biotinylated cholera toxin B subunit and secondary streptavidin conjugated to Texas Red. In Fig. 2D is an example showing labeling of filopodia by Texas Red-conjugated cholera toxin. Interestingly, we often noted that Texas Red-conjugated cholera toxin appeared as puncta localized along the processes, suggestive of rafts localized on the filopodia. We also detected staining of the filopodia with the raft marker DiIC<sub>16</sub> (Fig. 2E), although in this case, the labeling was not enriched in puncta. Furthermore, in some cases, we observed efficient labeling of filopodia by DiIC<sub>16</sub> that were barely detectable with the S<sub>15</sub>-Inp54p label (Fig. 2E, white arrowheads). This finding is again suggestive of enrichment of raft membranes in the cell processes. We conclude from these data that the filopodia in cells that expressed S<sub>15</sub>-Inp54p contained membrane rafts, and this may reflect enrichment of PIP<sub>2</sub> in membrane rafts upon S<sub>15</sub>-Inp54p expression.


**S<sub>15</sub>-Inp54p-dependent Changes in Cell Morphology Are Phosphatidylinositol 3-Kinase (PI3K)-dependent**—An important effector of PIP<sub>2</sub> signaling in membrane-actin interactions is the



**FIGURE 4. T cells expressing S<sub>15</sub>-Inp54p exhibit increased cell spreading in a PI3K-dependent manner.** A, confocal (upper panels) and differential interference contrast (DIC; lower panels) images of T cells expressing L<sub>10</sub>-Inp54p, S<sub>15</sub>-Inp54p, or L<sub>10</sub>-GFP. One set of cells expressing S<sub>15</sub>-Inp54p was treated with wortmannin (*Wm*) before fixation. The arrowheads in the S<sub>15</sub>-Inp54p sample indicate the edges of cell spreading. Scale bars = 5 μm. B, averaged results measuring the surface area of transfected Jurkat T cells seeded onto poly-L-lysine-coated coverslips. The data are from 60 cells measured in three independent trials using differential interference contrast imaging. \*\*\*, *p* ≤ 0.005 by Student's *t* test; NS (not significant), *p* > 0.05.

PI3K product PIP<sub>3</sub> (3). To determine whether the T cell morphology upon S<sub>15</sub>-Inp54p expression was PIP<sub>3</sub>-dependent, we measured cells expressing S<sub>15</sub>-Inp54p and treated with wortmannin. Cell imaging showed that wortmannin inhibited the membrane ruffling and filopodia that occurred in the untreated cells (Fig. 3A), and quantitation showed that wortmannin reduced the average number of filopodia by 10-fold (Fig. 3B). We also observed that washing away the wortmannin following drug treatment resulted in a return of the membrane ruffling and filopodia 2 h later (Fig. 3A, right panel), albeit not to the number measured in untreated cells (Fig. 3B). We interpret these data as evidence that the cell morphologies that occurred upon S<sub>15</sub>-Inp54p expression were PI3K-dependent.

**Altered Cell Spreading by Targeted Inp54p Expression**—Cell spreading occurs by activation of surface adhesion molecules, many of which are PIP<sub>2</sub>-dependent (39). Similarly, we observed in T cells expressing S<sub>15</sub>-Inp54p an increase in cell spreading on poly-L-lysine, often represented by an extension of a thin sheet of membrane from the cell body (Fig. 4A, arrowheads). We quantitated the cell spreading by measuring the area of the cell where it contacted the substratum, and this showed that S<sub>15</sub>-Inp54p caused a 2–3-fold increase in the cell area over that of cells expressing either L<sub>10</sub>-GFP or L<sub>10</sub>-Inp54p. Furthermore, wortmannin inhibited the S<sub>15</sub>-Inp54p-dependent spreading



**FIGURE 5. L<sub>10</sub>-Inp54p inhibits actin capping in stimulated T cells.** *A*, differential interference contrast (DIC) and confocal images of stimulated Jurkat T cells expressing L<sub>10</sub>-Inp54p, S<sub>15</sub>-Inp54p, L<sub>10</sub>-GFP, or L<sub>10</sub>-GFP treated with neomycin (Neo). Following stimulation, the samples were stained with Texas Red-conjugated phalloidin to detect F-actin. The fluorescence intensities are represented by pseudocolor, and the color assignment for intensity values is shown at the bottom. The asterisks indicate the positions of the antibody-coated beads. The arrows indicate actin-enriched membrane caps at the cell-bead interface. *B*, histograms of the relative enrichment of F-actin at the bead-cell interface measured in ~100 bead-cell conjugates. *C*, quantitation of the frequency of F-actin capping of each sample measured using confocal microscopy. A cell was scored as positive for capping when the mean fluorescence intensity of the bead-cell interface divided by the mean fluorescence intensity of the rest of the cell was 1.5 or greater. Percent cells positive for capping for each sample is graphed. The results were averaged from 90 separate bead-cell conjugates measured in three separate trials. \*\*,  $p \leq 0.01$  by Student's *t* test; \*\*\*,  $p \leq 0.005$ ; NS (not significant),  $p > 0.05$ .

(Fig. 4, *A* and *B*). Thus, the increased spreading from S<sub>15</sub>-Inp54p expression was also a PI3K-dependent property.

**Raft-targeted Inp54p Inhibits T Cell Capping following Stimulation**—T cells stimulated by cross-linking the T cell receptor (TCR) generate actin-rich membrane caps at the site of receptor cross-linking (40). To determine the effect of the membrane-targeted Inp54p molecules on membrane capping, transfected T cells were stimulated using 6- $\mu$ m polystyrene beads coated with an antibody specific to human CD3 (OKT3). To detect the capping, samples were fixed and stained with Texas Red-conjugated phalloidin and measured by confocal microscopy.

In Fig. 5*A* are representative images of bead-cell conjugates that show an inhibition of capping by L<sub>10</sub>-Inp54p expression. For example, the cells that expressed either S<sub>15</sub>-Inp54p or control L<sub>10</sub>-GFP exhibited a 2–3-fold enrichment of F-actin at the bead-cell interface, but the cells that expressed L<sub>10</sub>-Inp54p demonstrated no such capping. Furthermore, pretreating cells expressing L<sub>10</sub>-GFP with neomycin to sequester PIP<sub>2</sub> (41) also inhibited the T cell capping, and this is consistent with the inhibition by L<sub>10</sub>-Inp54p occurring upon phosphatase-dependent changes in the PIP<sub>2</sub> pools. The inhibition of T cell capping by L<sub>10</sub>-Inp54p and neomycin is also represented by the histograms in Fig. 5*B*, which represents data from measuring the relative fluorescence enrichment at the bead-cell interface of ~100 conjugates. Finally, in a separate analysis, cells were scored as capped if the average intensity at the bead-cell inter-


face was 50% or greater than the remaining membrane. The fraction of cell-bead conjugates in each sample that exhibited capping under this criterion is plotted in Fig. 5*C*, and these data show that the inhibition by L<sub>10</sub>-Inp54p was both specific and statistically significant.

PIP<sub>2</sub> is important for a TCR-dependent Ca<sup>2+</sup> flux that drives remodeling of the cell cytoskeleton and associated membrane (35). Accordingly, one interpretation of the results in Fig. 5 is that the reduced actin capping by L<sub>10</sub>-Inp54p and neomycin is due to an inhibition of the TCR-dependent Ca<sup>2+</sup> flux. However, in contrast to the capping, we observed that neither L<sub>10</sub>-Inp54p nor S<sub>15</sub>-Inp54p significantly affected the total Ca<sup>2+</sup> flux relative to control cells (Fig. 6, *A* and *B*). Furthermore, the add-back assays in Fig. 6 (*C* and *D*) show that the Inp54p constructs also did not affect the release of either intracellular Ca<sup>2+</sup> stores or store-operated channels. We therefore conclude that the inhibition of capping by L<sub>10</sub>-Inp54p did not occur by blocking Ca<sup>2+</sup> signals downstream of the TCR.

## DISCUSSION

Membrane fractionation experiments show that a significant pool of cellular PIP<sub>2</sub> associates with the cholesterol-dependent membrane rafts (10, 11). However, the functional significance of PIP<sub>2</sub> compartmentalization has been unclear and even controversial. In this study, we used separate targeted forms of the PIP<sub>2</sub>-specific phosphatase Inp54p to measure the properties of





**FIGURE 6. Ca<sup>2+</sup> flux in stimulated T cells is not altered by membrane-targeted Inp54p expression.** *A*, Intracellular Ca<sup>2+</sup> flux following TCR stimulation of Jurkat T cells expressing L<sub>10</sub>-Inp54p, S<sub>15</sub>-Inp54p, or L<sub>10</sub>-GFP. T cells labeled with Indo-1 were measured by flow cytometry and stimulated with OKT3 antibody (asterisks). Ionomycin addition is indicated by the black arrowheads. *B*, The total intracellular Ca<sup>2+</sup> flux averaged from three independent trials. *C*, The store-operated Ca<sup>2+</sup> flux was measured the same as (*A*), but cells were measured in buffer containing 0.05 μM EGTA to discriminate between flux from intracellular stores and flux from store-operated channels. Ca<sup>2+</sup> indicates the time point when Ca<sup>2+</sup> was added. *D*, The Ca<sup>2+</sup> flux from store-operated channels averaged from three separate trials. In *B* and (*D*), NS, *p* > 0.05 by Student's *t* test.

PIP<sub>2</sub> in raft and nonraft fractions. Specifically, Inp54p was either targeted to the raft fraction using the membrane anchor of the Src family kinase Lck or restricted to the nonraft fraction using the membrane anchor of Src. Consistent with the membrane raft model, our data show phenotypes that correspond to specific changes in the raft-associated pool of PIP<sub>2</sub>. For example, expression of S<sub>15</sub>-Inp54p increased the fraction of PIP<sub>2</sub> in the raft fraction, and this coincided with increased membrane ruffling, cell spreading, and growth of surface filopodia. Conversely, L<sub>10</sub>-Inp54p caused a decrease in raft-associated PIP<sub>2</sub>, and this coincided with cells that were smooth in appearance and void of membrane ruffles and filopodia as well as inhibited in their TCR-dependent capping.

Neither Inp54p molecule significantly changed the amount of total PIP<sub>2</sub>, further indicating that the phenotypes reported here were due to changes in discrete pools of PIP<sub>2</sub> rather than its global levels in the membrane. In the case of S<sub>15</sub>-Inp54p, the enrichment of raft PIP<sub>2</sub> was offset by a decrease in nonraft PIP<sub>2</sub>. However, no such offset that accommodated a decrease in raft

PIP<sub>2</sub> by L<sub>10</sub>-Inp54p expression was observed. One explanation for this discrepancy is that L<sub>10</sub>-Inp54p decreased the total PIP<sub>2</sub>, but below a level that was detectable by our method.

One possible mechanism for the enrichment of PIP<sub>2</sub> in rafts by S<sub>15</sub>-Inp54p is an increase in the expression of protein factors such as MARCKS (myristoylated alanine-rich C kinase substrate) and GAP-43. These proteins bind PIP<sub>2</sub> and cause its partitioning into raft-like liquid-ordered phase lipids (49, 50). Alternatively, depletion of nonraft PIP<sub>2</sub> may activate synthesis of PIP<sub>2</sub> specifically in the membrane rafts. Overall, the similar level of total PIP<sub>2</sub> in cells expressing the targeted phosphatases shows a coupling of PIP<sub>2</sub> synthesis with its consumption by Inp54p. PIP<sub>2</sub> levels in cell membranes in general undergo extensive regulation, underscored by the quick re-establishment of steady-state levels following its hydrolysis by phospholipase C (PLC) during cell activation (51). Substantial reductions of PIP<sub>2</sub> by drug treatment have global effects on plasma membrane structure (19), and this reflects the multiplicity of functions of PIP<sub>2</sub> in establishing and maintaining membrane architecture. Our data show that at least some of the functions of PIP<sub>2</sub> are regulated by its compartmentalization between raft and nonraft membrane fractions.

Interestingly, the membrane ruffling and cell spreading brought about by S<sub>15</sub>-Inp54p were sensitive to wortmannin, showing that these changes occur through a PIP<sub>3</sub>-dependent mechanism. This could occur through basal PI3K activity acting on the elevated raft-associated PIP<sub>2</sub>, thereby elevating the PIP<sub>3</sub> content of the membrane and activating PIP<sub>3</sub>-dependent enzymes. Jurkat cells lack expression of the PIP<sub>3</sub>-specific phosphatase PTEN, and this will allow for an accumulation of PIP<sub>3</sub> (42). However, the S<sub>15</sub>-Inp54p-dependent morphology was not restricted to Jurkat cells because we also observed extensive membrane ruffling and filopodia in HeLa cells transfected with this construct (data not shown). Interestingly, expression of dominant-negative and constitutively active forms of the GTPase Rac in Jurkat cells generates cell morphologies similar to those we report here for L<sub>10</sub>-Inp54p and S<sub>15</sub>-Inp54p, respectively (43). Rac is a downstream effector of the guanine nucleotide exchange factor Vav (44), which itself is a PIP<sub>3</sub>-dependent enzyme. Accordingly, the changes in cell phenotype that we evidenced with the mem-

brane-targeted Inp54p molecules may reflect signaling in the Vav-Rac pathway affected by the altered levels of raft PIP<sub>2</sub>.

In stimulated T cells, PLCγ1 is recruited to the plasma membrane through binding to LAT (linker of activated T cells) (45, 46). Membrane recruitment of PLCγ1 is followed by production of inositol 1,4,5-trisphosphate through hydrolysis of PIP<sub>2</sub>, which then serves as a second messenger to initiate the TCR-dependent Ca<sup>2+</sup> flux. LAT is constitutively associated with membrane rafts (47), suggesting that much of the PLCγ1 is proximal to raft pools of PIP<sub>2</sub>. However, our data show that reducing these pools using L<sub>10</sub>-Inp54p did not significantly affect the Ca<sup>2+</sup> flux. One interpretation of this finding is that PLCγ1 utilizes nonraft PIP<sub>2</sub> more than predicted based on the proximity of LAT to raft PIP<sub>2</sub>. Utilization of nonraft PIP<sub>2</sub> by LAT-associated PLCγ1 may also account for the ability of a nonraft form of LAT to fully restore the TCR-dependent Ca<sup>2+</sup> flux when expressed in LAT-deficient thymocytes (48). Altogether, these findings illustrate the caution that should be exercised in interpreting membrane fractionation data as well as the complexities relating to regulation and activation of PIP<sub>2</sub>-dependent signaling.

In contrast to the notion of membrane domains enriched with PIP<sub>2</sub>, one recent study using the pleckstrin homology (PH) domain of PLCδ1 to detect PIP<sub>2</sub> did not observe clustering of the lipid in the plasma membrane (51). PH domains are a useful tool in qualitative measurements of phosphoinositides, such as detecting their turnover during cell signaling (52, 53). However, their utility in quantitative measurements is less certain. For example, the level of detection of the lipids by the probes is likely proportional to their level of expression, which itself will vary from cell to cell in an individual trial and between separate trials in each experiment. Furthermore, PH domains are often nonspecific in nature because many bind efficiently to more than one phosphoinositide species or their metabolites (54). For example, the PH domain from PLCδ1 binds both PIP<sub>2</sub> and the PLC product inositol 1,4,5-trisphosphate (55). Accordingly, additional experiments using more quantitative probes may demonstrate properties for the PIP<sub>2</sub> membrane distribution that are more consistent with its enrichment in membrane rafts.

Altogether, the factors that affect protein and lipid distributions in cell membranes remain an ongoing topic of studies of membrane structure. The membrane localization of PIP<sub>2</sub> is a particularly important question because of its pivotal role in many membrane functions and cell signaling events. Membrane fractionation experiments show that a significant fraction of PIP<sub>2</sub> occurs in membrane rafts. We provide evidence here showing that this represents a compartmentalization of PIP<sub>2</sub> functions in T cells, where raft-associated PIP<sub>2</sub> corresponds to a discrete pool of molecules that confer distinct phenotypes on T cells when modified using targeted PIP<sub>2</sub>-specific phosphatases. Further experiments are, however, necessary to better define the character of raft-associated PIP<sub>2</sub> in biological membranes and the mechanism for PIP<sub>2</sub> enrichment in these structures.

*Acknowledgments*—We thank Jacob Bass (Oklahoma Medical Research Foundation Flow Cytometry Core Facility) for flow cytometry assistance, L. Tsiokas for helpful discussions, and K. Moore and M. Coggeshall for comments on the manuscript.

## REFERENCES

- Di Paolo, G., and De Camilli, P. (2006) *Nature* **443**, 651–657
- Majerus, P. W., Connolly, T. M., Deckmyn, H., Ross, T. S., Bross, T. E., Ishii, H., Bansal, V. S., and Wilson, D. B. (1986) *Science* **234**, 1519–1526
- Rameh, L. E., and Cantley, L. C. (1999) *J. Biol. Chem.* **274**, 8347–8350
- McLaughlin, S., Wang, J., Gambhir, A., and Murray, D. (2002) *Annu. Rev. Biophys. Biomol. Struct.* **31**, 151–175
- Ilani, T., Khanna, C., Zhou, M., Veenstra, T. D., and Bretscher, A. (2007) *J. Cell Biol.* **179**, 733–746
- Stosser, T. P., Condeelis, J., Cooley, L., Hartwig, J. H., Noegel, A., Schleicher, M., and Shapiro, S. S. (2001) *Nat. Rev. Mol. Cell Biol.* **2**, 138–145
- Takenawa, T., and Suetsugu, S. (2007) *Nat. Rev. Mol. Cell Biol.* **8**, 37–48
- Raucher, D., Stauffer, T., Chen, W., Shen, K., Guo, S., York, J. D., Sheetz, M. P., and Meyer, T. (2000) *Cell* **100**, 221–228
- Engelman, D. M. (2005) *Nature* **438**, 578–580
- Pike, L. J., and Casey, L. (1996) *J. Biol. Chem.* **271**, 26453–26456
- Pike, L. J., and Miller, J. M. (1998) *J. Biol. Chem.* **273**, 22298–22304
- Laux, T., Fukami, K., Thelen, M., Golub, T., Frey, D., and Caroni, P. (2000) *J. Cell Biol.* **149**, 1455–1472
- Tian, T., Harding, A., Inder, K., Plowman, S., Parton, R. G., and Hancock, J. F. (2007) *Nat. Cell Biol.* **9**, 905–914
- Rodgers, W., and Rose, J. K. (1996) *J. Cell Biol.* **135**, 1515–1523
- Young, R. M., Zheng, X., Holowka, D., and Baird, B. (2005) *J. Biol. Chem.* **280**, 1230–1235
- Heerklotz, H. (2002) *Biophys. J.* **83**, 2693–2701
- Heerklotz, H., Szadkowska, H., Anderson, T., and Seelig, J. (2003) *J. Mol. Biol.* **329**, 793–799
- Pizzo, P., Giurisato, E., Tassi, M., Benedetti, A., Pozzan, T., and Viola, A. (2002) *Eur. J. Immunol.* **32**, 3082–3091
- Kwik, J., Boyle, S., Fooksman, D., Margolis, L., Sheetz, M. P., and Edidin, M. (2003) *Proc. Natl. Acad. Sci. U. S. A.* **100**, 13964–13969
- Hancock, J. F. (2006) *Nat. Rev. Mol. Cell Biol.* **7**, 456–462
- Chichili, G. R., and Rodgers, W. (2007) *J. Biol. Chem.* **282**, 36682–36691
- Rodgers, W., Farris, D., and Mishra, S. (2005) *Trends Immunol.* **26**, 97–103
- Jacobson, K., Mouritsen, O. G., and Anderson, R. G. (2007) *Nat. Cell Biol.* **9**, 7–14
- Parmryd, I., Adler, J., Patel, R., and Magee, A. I. (2003) *Exp. Cell Res.* **285**, 27–38
- Huang, S., Lifshitz, L., Patki-Kamath, V., Tuft, R., Fogarty, K., and Czech, M. P. (2004) *Mol. Cell Biol.* **24**, 9102–9123
- Golub, T., and Caroni, P. (2005) *J. Cell Biol.* **169**, 151–165
- Rozelle, A. L., Machesky, L. M., Yamamoto, M., Driessens, M. H., Insall, R. H., Roth, M. G., Luby-Phelps, K., Marriott, G., Hall, A., and Yin, H. L. (2000) *Curr. Biol.* **10**, 311–320
- Wiradajaja, F., Ooms, L. M., Whisstock, J. C., McColl, B., Helfenbaum, L., Sambrook, J. F., Gething, M. J., and Mitchell, C. A. (2001) *J. Biol. Chem.* **276**, 7643–7653
- Resh, M. D. (1994) *Cell* **76**, 411–413
- Field, K. A., Holowka, D., and Baird, B. (1995) *Proc. Natl. Acad. Sci. U. S. A.* **92**, 9201–9205
- Rodgers, W. (2002) *BioTechniques* **32**, 1044–1051
- Jordan, S., and Rodgers, W. (2003) *J. Immunol.* **171**, 78–87
- Pettitt, T. R., Dove, S. K., Lubben, A., Calaminus, S. D., and Wakelam, M. J. (2006) *J. Lipid Res.* **47**, 1588–1596
- Rodgers, W., and Zavzavadjian, J. (2001) *Exp. Cell Res.* **267**, 173–183
- Penninger, J. M., and Crabtree, G. R. (1999) *Cell* **96**, 9–12
- Acuto, O., and Cantrell, D. (2000) *Annu. Rev. Immunol.* **18**, 165–184
- Villalba, M., Bi, K., Rodriguez, F., Tanaka, Y., Schoenberger, S., and Altman, A. (2001) *J. Cell Biol.* **155**, 331–338
- Charras, G. T., Hu, C. K., Coughlin, M., and Mitchison, T. J. (2006) *J. Cell Biol.* **175**, 477–490
- Caroni, P. (2001) *EMBO J.* **20**, 4332–4336
- Roelants, G., Forni, L., and Pernis, B. (1973) *J. Exp. Med.* **137**, 1060–1077
- Gabev, E., Kasianowicz, J., Abbott, T., and McLaughlin, S. (1989) *Biochim. Biophys. Acta* **979**, 105–112
- Shan, X., Czar, M. J., Bunnell, S. C., Liu, P., Liu, Y., Schwartzberg, P. L., and



## Membrane Rafts in PIP<sub>2</sub> Signaling

- Wange, R. L. (2000) *Mol. Cell. Biol.* **20**, 6945–6957
43. Arrieumerlou, C., Randriamampita, C., Bismuth, G., and Trautmann, A. (2000) *J. Immunol.* **165**, 3182–3189
44. Jaffe, A. B., and Hall, A. (2005) *Annu. Rev. Cell Dev. Biol.* **21**, 247–269
45. Zhang, W., Sloan-Lancaster, J., Kitchen, J., Tribble, R. P., and Samelson, L. E. (1998) *Cell* **92**, 83–92
46. Zhang, W., Irvin, B. J., Tribble, R. P., Abraham, R. T., and Samelson, L. E. (1999) *Int. Immunol.* **11**, 943–950
47. Zhang, W., Tribble, R. P., and Samelson, L. E. (1998) *Immunity* **9**, 239–246
48. Zhu, M., Shen, S., Liu, Y., Granillo, O., and Zhang, W. (2005) *J. Immunol.* **174**, 31–35
49. Wang, J., Arbuzova, A., Hangyas-Mihalyne, G., and McLaughlin, S. (2001) *J. Biol. Chem.* **276**, 5012–5019
50. Tong, J., Nguyen, L., Vidal, A., Simon, S. A., Skene, J. H., and McIntosh, T. J. (2008) *Biophys. J.* **94**, 125–133
51. van Rheenen, J., Achame, E. M., Janssen, H., Calafat, J., and Jalink, K. (2005) *EMBO J.* **24**, 1664–1673
52. Stauffer, T. P., Ahn, S., and Meyer, T. (1998) *Curr. Biol.* **8**, 343–346
53. Varnai, P., and Balla, T. (1998) *J. Cell Biol.* **143**, 501–510
54. Lemmon, M. A., and Ferguson, K. M. (2001) *Biochem. Soc. Trans.* **29**, 377–384
55. Varnai, P., Lin, X., Lee, S. B., Tuymetova, G., Bondeva, T., Spat, A., Rhee, S. G., Hajnoczky, G., and Balla, T. (2002) *J. Biol. Chem.* **277**, 27412–27422